EX-103 Drug Asset Due Diligence Report 2026

This EX-103 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether EX-103 can convert its Bispecific T-cell Engager (BiTE) profile and CD20 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	EX-103 (query alias: EX-103)
Modality / target	Bispecific T-cell Engager (BiTE); CD20 x CD3; CD20 inhibitors, CD3 stimulants
Highest global status	Phase 1/2
Originator	Excelmab, Inc.
Active developers	Excelmab, Inc.

The MCP disease footprint includes CD20 positive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06021678	Phase 1/2	Recruiting	415	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

3103EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1/2; n=not disclosed; evaluation: Not stated in English source. Reported fields: Adverse Event: CRS = CRS events were the most common treatment related adverse events and occurred in 66.7% of the patients, with 50.7% grade 1, 14.5% grade 2, one patient (1.4%) experienced grade 3, and no higher events occurred.

EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial.

Phase 1/2; n=23; evaluation: Positive. Reported fields: CRS = All CRS events were grade (Gr) 1-2 (Gr 1: 78.3%, Gr 2: 13.0%), no Gr 3 or higher events

EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma

Phase 1; n=13; evaluation: Positive. Reported fields: AE = The most common adverse events were CRS and pyrexia, all were grade (Gr) 1-2, no Gr 3 or higher. Most CRS occurred in 1st or 2nd cycle, and resolved within 48 hours. No neurologic AE occurred. ; AE = The most common adverse events were CRS and pyrexia, all were grade (Gr) 1-2, no Gr 3 or higher. Most CRS occurred in 1st or 2nd cycle, and resolved within 48 hours. No neurologic AE occurred.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

EX-103 addresses CD20 positive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 84 matched transaction record(s) under the scope “target-level comparable: CD20 x CD3.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD20 x CD3 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-09	Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis	Preclinical	Financial terms not disclosed
2026-06-04	Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market	Approved	US$3.4M upfront; US$27.4M milestones
2026-05-26	Transaction title not available in English source	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, infection, and treatment logistics
Durability of response and antigen escape
Manufacturing scalability, release testing, and site readiness

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO